Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Hematological oncology·2026
Same author

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026
Same author

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

American journal of hematology·2026
Same author

Racial Disparities in Glioblastoma: Can We Untangle Biological From Nonbiological Forces?

JCO oncology practice·2026

Related Experiment Video

Updated: Jul 14, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Leslie L Muldoon1, Carole Soussain, Kristoph Jahnke

  • 1Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239-3098, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|June 1, 2007
PubMed
Summary

This review highlights the limited understanding of brain tumor chemotherapy, emphasizing the need for improved drug delivery across the blood-brain barrier (BBB) and other barriers for effective treatment.

More Related Videos

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery
08:22

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery

Published on: July 18, 2019

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

Related Experiment Videos

Last Updated: Jul 14, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice

Published on: February 24, 2023

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery
08:22

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery

Published on: July 18, 2019

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

Area of Science:

  • Neuro-oncology
  • Pharmacology
  • Cancer Therapy

Background:

  • Brain tumor chemotherapy lacks rational approaches, often relying on empirical data.
  • Primary brain tumors and CNS metastases present unique treatment challenges.
  • The blood-brain barrier (BBB) and tumor properties impede systemic chemotherapy efficacy.

Purpose of the Study:

  • To review preclinical and clinical pharmacology of brain tumor chemotherapy.
  • To evaluate brain tumor pharmacology studies published before October 2006.
  • To assess current knowledge gaps in brain tumor drug delivery and efficacy.

Main Methods:

  • Literature review of brain tumor pharmacology studies.
  • Analysis of drug delivery mechanisms across the blood-brain barrier (BBB).
  • Evaluation of studies on conventional and novel chemotherapeutics.

Main Results:

  • Brain tumor treatment primarily relies on empirical data, not prospective rational approaches.
  • Few brain tumors have well-defined optimal chemotherapeutic strategies.
  • Studies demonstrating actual drug concentrations and biological effects within brain tumors are scarce.

Conclusions:

  • Drug delivery across the blood-brain barrier (BBB), blood-tumor, and cerebrospinal fluid (CSF) barriers requires further investigation.
  • Innovative treatments and alternative delivery methods are crucial for CNS tumors.
  • Enhanced drug delivery to the central nervous system (CNS) and CSF is essential for improved outcomes.